Ophthalmic Business News

Visiox Pharmaceuticals has entered into a definitive merger agreement with Ocuvex Therapeutics, according to a press release.

As medical technology quickly evolves, practices in nearly all areas of medicine must frequently evaluate equipment upgrades and new purchases of new technology to stay at the forefront of patient care.

Healio’s recent FDA news in ophthalmology includes the approval of Enzeevu for neovascular age-related macular degeneration and a rare pediatric disease designation for an X-linked retinoschisis candidate.

My name is Jennifer Loh, and I'm an ophthalmologist in South Florida, but I did start my own practice about 8 years ago now.

The FDA granted rare pediatric disease designation to ATSN-201, a gene therapy candidate for the treatment of X-linked retinoschisis, according to a press release from Atsena Therapeutics.

Spencer Trask & Co. announced the launch of Signal12, a clinical-stage dry eye company that plans to advance Pro-ocular for the treatment of dry eye disease, according to a press release.

In this episode, Dagny Zhu, MD, and Cathleen McCabe, MD, discuss the unpredictable path of careers, leadership in management and opportunities for growth with Nikie Walker, EdD.

Eclipse Life Sciences has enrolled and dosed the first patient in the BETTIS-1 phase 2 clinical trial investigating the EC-104 implant for the treatment of diabetic macular edema, according to a press release.

The FDA approved the Enzeevu 2 mg vial kit and prefilled syringe for intravitreal injection for the treatment of neovascular age-related macular degeneration, according to a press release from Sandoz.

As your paycheck grows, so does your discretionary spending and saving. While it is easy to spend, it is not always clear where to invest your next dollar intended for future spending.